Kelly Corbet
Overview
Explore the profile of Kelly Corbet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
186
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maung K, Ramalingam S, Chaudhry M, Ren Y, Jung S, Romero K, et al.
PLoS One
. 2020 Sep;
15(9):e0238824.
PMID: 32915853
Allogeneic-HCT (allo-HCT), while potentially curative, can result in significant complications including graft versus host disease (GVHD). Prior studies suggest that metabolic syndrome may be one risk factor for GVHD. We...
2.
Tanaka J, Young R, Heston S, Jenkins K, Spees L, Sung A, et al.
Biol Blood Marrow Transplant
. 2020 Jul;
26(11):2053-2060.
PMID: 32682948
Certain anaerobic bacteria are important for maintenance of gut barrier integrity and immune tolerance and may influence the risk of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT)....
3.
Foster G, Grant M, Thomas S, Cameron B, Raiff D, Corbet K, et al.
Biol Blood Marrow Transplant
. 2020 May;
26(9):1597-1606.
PMID: 32450288
Despite a well-established risk of chronic kidney disease (CKD) after allogeneic hematopoietic cell transplant (allo-HCT), the benefits of using nephrotoxic anti-infective agents to treat serious peritransplant infections often outweigh this...
4.
Anand S, Thomas S, Corbet K, Gasparetto C, Long G, Lopez R, et al.
Biol Blood Marrow Transplant
. 2017 Jul;
23(11):1949-1954.
PMID: 28729147
Treatment-related mortality (TRM) remains elevated in adult patients undergoing umbilical cord blood transplantation (UCBT), including an early rise in TRM suggestive of excessive toxicity associated with the standard myeloablative total...
5.
Anand S, Thomas S, Hyslop T, Adcock J, Corbet K, Gasparetto C, et al.
Biol Blood Marrow Transplant
. 2017 Apr;
23(7):1151-1157.
PMID: 28392378
Delayed hematopoietic recovery contributes to increased infection risk following umbilical cord blood (UCB) transplantation. In a Phase 1 study, adult recipients of UCB stem cells cultured ex vivo for 3...
6.
Huang L, Bacon W, Cirrincione C, Peterson B, Long G, Rizzieri D, et al.
Hematol Oncol
. 2017 Jan;
35(4):752-759.
PMID: 28105753
We retrospectively studied 340 fit patients with multiple myeloma (MM) who underwent autologous stem cell transplantation (ASCT). We hypothesized that progression-free survival (PFS) of older patients was non-inferior to that...
7.
Green M, Chao N, Chhabra S, Corbet K, Gasparetto C, Horwitz A, et al.
J Hematol Oncol
. 2016 Aug;
9(1):71.
PMID: 27535663
Background: The binding of CXCR4 with its ligand (stromal-derived factor-1) maintains hematopoietic stem/progenitor cells (HSPCs) in a quiescent state. We hypothesized that blocking CXCR4/SDF-1 interaction after hematopoietic stem cell transplantation...
8.
Sung A, Sung J, Thomas S, Hyslop T, Gasparetto C, Long G, et al.
Clin Infect Dis
. 2016 Aug;
63(8):999-1006.
PMID: 27481873
Background: Respiratory viral infections (RVIs) are frequent complications of hematopoietic stem cell transplant (HSCT). Surgical masks are a simple and inexpensive intervention that may reduce nosocomial spread. Methods: In this...
9.
Tuchman S, Bacon W, Huang L, Long G, Rizzieri D, Horwitz M, et al.
J Clin Apher
. 2014 Oct;
30(3):176-82.
PMID: 25293363
High-dose cyclophosphamide (Cy) is frequently employed for peripheral blood mobilization of hematopoietic stem cells before high-dose chemotherapy with autologous stem cell transplantation (ASCT) in multiple myeloma (MM). The benefit of...
10.
Xiao B, Wang Y, Li W, Baker M, Guo J, Corbet K, et al.
Blood
. 2013 Sep;
122(19):3365-75.
PMID: 24041574
Acute graft-versus-host disease (aGVHD) is the leading cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Approximately 35% to 50% of HCT recipients develop aGVHD; however, there are...